Federal Register / Vol. 53, No. 218 / Thursday, November 10, 1988 / Notices 
45591 
regional office (see Appendix A), and 
specify Health Insurance Number. 
RECORO ACCESS PflOCEDURES: 
Same as notification procedures. 
Requestors should reasonably specify 
the information in the records being 
sought. You may also request an 
accounting of disclosures that have been 
made of your records, if any. (These 
procedures are in accordance with 
Departmental Regulations (45 CFR 
5b. 5(a)(2).] 
CONTESTING RECORD PROCEDURES: 
Contact the system manager named 
above and reasonably identify/the 
record and specify the information to be 
contested, and state the corrective 
action sought and your reasons for 
requesting the correctioiy along with 
information to show hoiv the record is 
inaccurate, incomplete; untimely, 
irrelevant, or otherwise in need of 
correction. (Theseprocedures are in 
accordance with Departmental 
Regulations 45 GrR 5b.7.) 
RECORD SOURCE'CATEGORIES: 
These records will be generated by 
the PRO from data received from the 
servicing fiscal intermediary (FI) or 
carrier responsible for the processing of 
Medicare hospital bills and data 
generated by the PRO itself as a direct 
result of medical review performed. 
Other sources would include Medicare 
beneficiaries, congressional dffice, 
HCFA. Medicare providers, /Medicare 
intermediary/carrier. Office of the 
Inspector General, etc. The magnetic 
tape record will only include 
information to be compiled in the data 
base (e.g., Peer Review/Organizations 
identifier, HIC, admission/service and 
discharge dates, review selection and 
results). 
SYSTEMS EXEMPTED FROM CERTAIN 
PROVISIONS OF THE ApT: 
None. 
Appendix A — Health Care Financing 
Administration Ro&ional Offices 
I Boston. Project Officer, Peer Review 
Organization. Aoom 1309, JFK Federal 
Building, Boston, Massachusetts 022032. 
II New York. /Project Officer, Peer Review 
Organization. Room 3004. 26 Federal Plaza. 
New YorkyNew York 10278. 
III Philadelphia, Project Officer. Peer 
Review Organization. 3535 Market Street, 
P.O. Box 7760, Philadelphia. Pennsylvania 
19101. 
IV Atlanta, Project Officer, Peer Review 
Organization. Suite 601, 101 Marietta 
Toiler, Atlanta, Georgia 30323 
V Chicago, Project Officer, Peer Review 
Organization, Suite A-835, 175 W. Jackson 
Boulevard, Chicago, Illinois 60604. 
■ ect Officer, Peer Review 
Room 2000. 1200 Main T6wer 
as, Texas 75202. 
y, Project Officer. Deer 
lization. New Federal Office 
n 235, 601 East/lzth Street 
Missouri 64106. 
■oject OfHper, Peer Review 
Organization. Federal building, Room 574. 
1961 Stout Street, Denver. Colorado 80294. 
IX San Francisco, Breject Officer. Peer 
Review Organization. 14th Floor, 100 Van 
Ness Avenue. Jan Francisco. California 
94102. 
X Seattle. Project Officer. Peer Review 
Organization. Room 430A, 2901 Third 
Avenue. Seattle, Washington 98121. 
(FR Doc. 88-25979 Filed 11-9-88; 3:45 am] 
BILUNG CODE 4120-03-U 
National Institutes of Health 
Recombinant DNA Advisory 
Committee Human Gene Therapy 
Subcommittee; Meeting 
Pursuant to Pub. L 92-463, notice is 
hereby given of a meeting of the 
Recombinant DNA Advisory Committee 
Human Gene Therapy Subcommittee at 
the National Institutes of Health, 
Building 31C, Conference Room 10, 9000 
Rockville Pike, Bethesda, Maryland 
20892, on December 9, 1988, from 
approximately 9:00 a.m. to adjournment 
at approximately 5:00 p.m. The purpose 
of the meeting will be to review a human 
gene transfer protocol submitted by Drs. 
Steven A. Rosenberg, R. Michael Blaese, 
and W. French Anderson and to 
complete an information brochure on 
human gene therapy. This meeting will 
be open to the public. Attendance by the 
public will be limited to space available. 
Further information may be obtained 
from Ms. Rachel E. Levinson. Executive 
Secretary, Recombinant DNA Advisory 
Committee Human Gene Therapy 
Subcommittee, Office of Recombinant 
DNA Activities, National Institutes of 
Health, Building 31, Room B1C34, 
Bethesda, Maryland 20892, telephone 
(301) 496-9838, 
OMB’s "Mandatory Information 
Requirements forFederal Assistance 
Program Announcements" (45 FR 39592) 
requires a statement concerning the 
official government programs contained 
in the Catalog of Federal Domestic 
Assistance. Normally NIH lists in its 
announcements the number and title of 
affected individual programs for the 
guidance of the public. Because the 
guidance in this notice covers not only 
virtually every NIH program but also 
essentially every Federal research 
program in which DNA recombinant 
molecule techniques could be used, it 
has been determined to be not cost 
effective or in the public interest to 
attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be lnlcuded as many 
Federal agencies, as well as private 
organizations, both national and 
international, have elected to follow the 
NIH Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of Federal 
Domestic Assistance are affected. 
Dated: November 3. 1988. 
Betty J. Beveridge, 
Committee Management Officer. NIH. 
(FR Doc. 88-26070 Filed 11-9-88: 8:45 am] 
BILLING CODE 4140-01-M 
National Cancer Institute; Meeting of 
the Frederick Cancer Research Facility 
Advisory Committee 
Pursuant to Pub. L. 92-463, notice is 
hereby given of the meeting of the 
Frederick Cancer Research Facility 
(FCRF) Advisory Committee, National 
Cancer Institute, November 21-22, 1988, 
Building 549, Executive Board Room, at 
the NCI Frederick Cancer Research 
Facility, Frederick, Maryland 21701- 
1013. 
The meeting will be open to the public 
on November 21 from 8:30 a.m. to 
approximately 11 a.m. to discuss 
administrative matters, future meetings, 
budget, legislative update, and to hear 
from the Associate Director for FCRF on 
items of interest to NCI and the 
Committee, including progress made on 
development of AIDS vaccine. 
Attendance by the public will be limited 
to space available. 
In accordance with the provisions set 
forth in sections 552b(c)(4) and 
552b(c)(6), Title 5, U.S.C. and section 
10(d) of Pub. L 92-463, the meeting will 
be closed to the public on November 21 
from approximately 11 a.m. to recess 
and on November 22 from 8:30 a.m. to 
adjournment for site visit of research 
being conducted by the Basic Research 
Program’s Laboratory of Chemical and 
Physical Carcinogenesis. These 
discussions could reveal confidential 
trade secrets or commercial property 
6uch as patentable material, and 
personal information concerning 
individuals associated with the 
contractor, the disclosure of which 
would constitute a clearly unwarranted 
invasion of personal privacy. 
Mrs. Winifred Lumsden. Committee 
Management Officer, National Cancer 
Institute. Building 31, Room 10A06, 
National Institutes of Health, Bethesda, 
[ 278 ] 
Recombinant DNA Research, Volume 13 
